<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="277">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103256</url>
  </required_header>
  <id_info>
    <org_study_id>YHP1701-301</org_study_id>
    <nct_id>NCT03103256</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of YHP1701</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel-group Phase III Clinical Trial to Evaluate the Efficacy and Safety of YHP1701 Fixed Dose Combination in Patients With Dyslipidemia and Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine superiority of YHP1701 comparing to each
      monotherapy in patient with hypertension and primary hypercholesterolemia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change of LDL-Cholesterol</measure>
    <time_frame>0, 8 weeks</time_frame>
    <description>LDL-Cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of mean seated Systolic Blood Pressure</measure>
    <time_frame>0, 8 weeks</time_frame>
    <description>Blood Pressure</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Hypertension and Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>YHP1701</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PO, Once daily (QD), 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YHR1703</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PO, Once daily (QD), 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YHR1704</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PO, Once daily (QD), 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHP1701</intervention_name>
    <description>PO, Once daily (QD), 8 weeks</description>
    <arm_group_label>YHP1701</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHR1703</intervention_name>
    <description>PO, Once daily (QD), 8 weeks</description>
    <arm_group_label>YHR1703</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHR1704</intervention_name>
    <description>PO, Once daily (QD), 8 weeks</description>
    <arm_group_label>YHR1704</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both man and woman who is over 19 years old

          -  Patient with dyslipidemia and hypertension

        Exclusion Criteria:

          -  sSBP difference is ≥20 mmHg or sDBP difference is ≥10 mmHg

          -  A history of cardiovascular disease

          -  Rhabdomyolysis, myopathy

          -  Hypertension or hypercholesterolemia due to secondary causes

          -  Uncontrolled diabetes

          -  Evidence of hepatic or renal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Song</last_name>
    <phone>82-2-828-0385</phone>
    <email>ejsong@yuhan.co.kr</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>March 22, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
